Lobby organisation
Amgen Inc
Company · Health & pharma · HQ: United States · Transparency Register entry
As of 7 November 2026, Amgen Inc appears in 19 declared MEP meetings (16 different MEPs), most often with European People's Party.
In their own words
“Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.”
Read the rest of the statementShow less of the statement
“Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential. Amgen was incorporated in California in 1980 and became a Delaware corporation in 1987. Amgen has a presence in approximately 100 countries worldwide. It operates in one business segment : human therapeutics.”
Stated goals from the organisation's own Transparency Register filing.
Who they meet, and when
Which groups they meet
Share of this organisation's 19 declared meetings, by the meeting MEP's political group.
Meetings by year
Declared meetings per calendar year, 2020–2026. Bar length is relative to its busiest year (9 in 2026). Hatched: 2026 is a part-year - the record runs to 6 Nov 2026.
Group is each MEP's current political group, not necessarily the one they sat with at the time. Shares are rounded to whole percent.
The MEPs they meet most
The 15 most recent declared meetings
| Date | MEP | Subject |
|---|---|---|
| 20 Oct 2026 | Tiemo Wölken | MDR/IVDR Revision and Biotech Act |
| 26 May 2026 | Ingeborg ter Laak | Biotech Act |
| 6 May 2026 | Nicola Zingaretti | Biotech Act |
| 29 Apr 2026 | Nicolás González Casares | Pharmaceutical Policy EU-US Trade |
| 28 Apr 2026 | Ingeborg ter Laak | Biotech Act |
| 22 Apr 2026 | Nicolás González Casares | Biotech - pharmaceutical side in the Biotech regulation |
| 21 Apr 2026 | Billy Kelleher | Bio Tech Act |
| 16 Apr 2026 | Wouter Beke | EU Biotech Act I |
| 14 Apr 2026 | Carlo Ciccioli | Biotech act |
| 8 Oct 2025 | Hildegard Bentele | Biotech |
| 23 Sep 2025 | Olivier Chastel | APAs briefing session on Biotech Act |
| 10 Sep 2025 | Vlad Vasile-Voiculescu | Meeting CMA |
| 16 Jul 2025 | Aurelijus Veryga | Innovative Therapies and Public Health Challenges |
| 22 Apr 2025 | Ingeborg ter Laak | Critical medicines act |
| 19 Feb 2025 | Angelika Niebler | EU Pharma Policy |
Meeting an MEP is a normal part of democratic life; the record is shown so anyone can see it.